Table 4.
Cost-effectiveness in the CMT and PVT group, with regards to the VAS and the ambulation and ADL scales at 1 week and at 3 and 12 months from treatment selection
| Type of treatment | 1 week | 3 months | 12 months |
|---|---|---|---|
| Cost-effectiveness VAS mean ± SD (range) | |||
| Medical therapy | 1079.27 ± 951.20*(195.55–1958.00) | 861.810 ± 639.94(122.96–1589.88) | 632.29 ± 528.32(165.37–1484.35) |
| Vertebroplasty | 435.70 ± 6.47*(413.85–473.12) | 480.17 ± 14.36(416.14–536.44) | 539.61 ± 39.23(439.96–772.63) |
| Cost-effectiveness ambulation mean ± SD (range) | |||
| Medical therapy | 1888.73 ± 1664.60*(391.10-N/A) | 4213.28 ± 3764.88*(553.34–11129.19) | 2149.78 ± 2013.23(440.99–5937.40) |
| Vertebroplasty | 1379.73 ± 50.36*(1103.60–1655.91) | 1560.54 ± 62.85*(1247.79–1877.53) | 1864.11 ± 84.71(1319.88–2575.44) |
| Cost-effectiveness ADL mean ± SD (range) | |||
| Medical therapy | 2518.30 ± 2219.47*(391.10-N/A) | 3159.96 ± 2615.63(1106.68–11129.19) | 1869.37 ± 1134.28(440.99–3958.26) |
| Vertebroplasty | 1226.43 ± 65.49*(827.70–1655.40) | 1498.12 ± 54.18(1247.79–1877.53) | 1708.77 ± 90.03(1319.88–2575.44) |
* Significant difference between groups (P < 0.05; Mann–Whitney U test)
N/A Data not available as one or more patients presented no reduction of the scale’s value